Back to top
more

Castle Biosciences (CSTL)

(Real Time Quote from BATS)

$24.63 USD

24.63
7,944

+0.30 (1.23%)

Updated May 6, 2024 10:02 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (80 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Earnings Preview: Castle Biosciences, Inc. (CSTL) Q2 Earnings Expected to Decline

by Zacks Equity Research

Castle Biosciences, Inc. (CSTL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Castle Biosciences, Inc. (CSTL) delivered earnings and revenue surprises of -19.40% and 6.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

C4 Therapeutics, Inc. (CCCC) delivered earnings and revenue surprises of -6.56% and 0.16%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Castle Biosciences, Inc. (CSTL) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Castle Biosciences, Inc. (CSTL) delivered earnings and revenue surprises of 41.86% and 6.89%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

The Joint Corp. (JYNT) Q4 Earnings Lag Estimates

by Zacks Equity Research

The Joint Corp. (JYNT) delivered earnings and revenue surprises of -87.50% and 1.01%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Castle Biosciences, Inc. (CSTL) Q4 Earnings Expected to Decline

by Zacks Equity Research

Castle Biosciences, Inc. (CSTL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Castle Biosciences, Inc. (CSTL) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Castle Biosciences, Inc. (CSTL) delivered earnings and revenue surprises of -34.29% and -0.79%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Castle Biosciences, Inc. (CSTL) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Castle Biosciences, Inc. (CSTL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Castle Biosciences, Inc. (CSTL) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Castle Biosciences, Inc. (CSTL) delivered earnings and revenue surprises of -17.24% and 19.21%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Castle Biosciences, Inc. (CSTL) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Castle Biosciences, Inc. (CSTL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Castle Biosciences, Inc. (CSTL) delivered earnings and revenue surprises of 22.73% and 33.14%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Castle Biosciences, Inc. (CSTL) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Castle Biosciences, Inc. (CSTL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Castle Biosciences, Inc. (CSTL) Moves 5.3% Higher: Will This Strength Last?

by Zacks Equity Research

Castle Biosciences, Inc. (CSTL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Castle Biosciences, Inc. (CSTL) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Castle Biosciences, Inc. (CSTL) delivered earnings and revenue surprises of -45.45% and 10.62%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Is a Surprise Coming for Castle Biosciences (CSTL) This Earnings Season?

by Zacks Equity Research

Castle Biosciences (CSTL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Castle Biosciences, Inc. (CSTL) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Castle Biosciences, Inc. (CSTL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Cassava Sciences (SAVA) to Post Q4 Earnings: What's in Store?

by Zacks Equity Research

Cassava Sciences (SAVA) will provide updates on its pipelinewhen it reports fourth-quarter 2020 results.

Bionano (BNGO) to Report Q4 Earnings: What's in the Offing?

by Zacks Equity Research

Bionano (BNGO) will provide updates on its revenues and earnings when it reports fourth-quarter and full-year 2020 results.

    Ocugen (OCGN) to Report Q4 Earnings: What's in the Cards?

    by Zacks Equity Research

    Ocugen (OCGN) will provide updates on its pipeline when it reports fourth-quarter 2020 results.

    Aerpio (ARPO) to Report Q4 Earnings: What's in the Cards?

    by Zacks Equity Research

    Aerpio (ARPO) will provide updates on its pipelinewhen it reports fourth-quarter 2020 results.

    Sorrento (SRNE) to Report Q4 Earnings: What's in the Cards?

    by Zacks Equity Research

    Sorrento (SRNE) will provide updates on sales, earnings and pipeline when it reports fourth-quarter 2020 results.

    What's in Store for Orchard Therapeutics (ORTX) Q4 Earnings?

    by Zacks Equity Research

    Orchard Therapeutics (ORTX) will provide updates on earnings, revenues of Strimvelis and the pipeline when it releases results for fourth-quarter 2020.

    Zacks.com featured highlights include: Catalyst Biosciences, UFP Industries, VeriSign, InMode and Castle Biosciences

    by Zacks Equity Research

    Zacks.com featured highlights include: Catalyst Biosciences, UFP Industries, VeriSign, InMode and Castle Biosciences

    Shrabana Mukherjee headshot

    5 Stocks Set to Pop on New Analyst Coverage

    by Shrabana Mukherjee

    Increased analyst coverage over the last few weeks might lead to solid price appreciation for stocks like Catalyst Biosciences (CBIO), UFP Industries (UFPI), VeriSign (VRSN), InMode (INMD) and Castle Biosciences (CSTL).

    Alexion (ALXN) Beats on Q3 Earnings & Sales, Ups '20 Guidance

    by Zacks Equity Research

    Alexion (ALXN) beats earnings and sales estimates in the third quarter of 2020.